EP Patent

EP3257501A1 — Multiple unit dosage form comprising a core with individual core units covered by a mucoadhesive material, and an enteric core coating

Assigned to Tillotts Pharma AG · Expires 2017-12-20 · 8y expired

What this patent protects

The present invention relates to a multiple unit dosage form comprising a core, wherein the core comprises a plurality of individual units, each unit comprising a pharmaceutically active ingredient and each unit being covered with a mucoadhesive material, and wherein the multiple…

USPTO Abstract

The present invention relates to a multiple unit dosage form comprising a core, wherein the core comprises a plurality of individual units, each unit comprising a pharmaceutically active ingredient and each unit being covered with a mucoadhesive material, and wherein the multiple unit dosage form further comprises an enteric core coating layer. The invention furthermore relates to the use of said multiple unit dosage form in the treatment of inflammatory disorders, especially for the gastrointestinal tract.

Drugs covered by this patent

Patent Metadata

Patent number
EP3257501A1
Jurisdiction
EP
Classification
Expires
2017-12-20
Drug substance claim
No
Drug product claim
No
Assignee
Tillotts Pharma AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.